1-3 of 3
Ana Kostic, MD
Close
Sort by
Journal Articles

A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Adults with Relapsed or Refractory B-Lineage Acute Leukemia (B-ALL) and Highly Aggressive Lymphoma

Amir T Fathi, MD, Uma Borate, MD, Daniel J. DeAngelo, MD PhD, Maureen M. O'Brien, MD, Tanya Trippett, MD, Bijal D Shah, Gregory A. Hale, MD, James M. Foran, MD, Lewis B. Silverman, MD, Raoul Tibes, MD PhD, Stuart Cramer, D.O., Melinda Pauly, MD, Stella Kim, Ana Kostic, MD, Xiaohui Huang, Yang Pan, PhD, Robert Chen
Journal: Blood
Blood (2015) 126 (23): 1328.
https://doi.org/10.1182/blood.V126.23.1328.1328
Published: 2015
Journal Articles

Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma

Craig H. Moskowitz, MD, Andres Forero-Torres, MD, Bijal D. Shah, MD, Ranjana Advani, MD, Paul Hamlin, MD, Stella Kim, MD, Ana Kostic, MD, Larissa Sandalic, MS, Baiteng Zhao, PhD, Michelle A. Fanale, MD
Journal: Blood
Blood (2014) 124 (21): 1741.
https://doi.org/10.1182/blood.V124.21.1741.1741
Published: 2014
Journal Articles

Development of Chronic Lymphocytic Leukemia (CLL) Reactive Cytotoxic T Lymphocytes after Non-Myeloablative Hematopoietic Stem Cell Transplant Correlates with Anti-Leukemia Response.

Tetsuya Nishida, MD, Ana Kostic, MD, David G. Maloney, MD, Rainer F. Storb, MD, Stanley R. Riddell, MD
Journal: Blood
Blood (2006) 108 (11): 413.
https://doi.org/10.1182/blood.V108.11.413.413
Published: 2006